保護中: Assess Commercial Readiness in Europe (draft)
Unlock Opportunities in Europe With EVERSANA
Related Articles
WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent
Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This conversation takes a closer look at the following topics: How to get past the perceived launch “red tape” in the EU Emerging regulatory, HTA, access, data and commercial routes that will begin to open up this market What a successful post-pandemic launch should look like and determine the steps you need to get there. Investments […]
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma with recent changes, including the Pharmaceutical Strategy for Europe. But one element of the European pharma industry that remains constant is product distribution through parallel trade. In 2012, parallel trade activity rose by up to 25% in some countries; but distributing a product across territories with diverse regulations, cultures and languages is complex. Now, there is an even more efficient way for manufacturers to distribute treatments in Europe. The answer is one end-to-end commercialization […]